JP2008526876A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526876A5
JP2008526876A5 JP2007550488A JP2007550488A JP2008526876A5 JP 2008526876 A5 JP2008526876 A5 JP 2008526876A5 JP 2007550488 A JP2007550488 A JP 2007550488A JP 2007550488 A JP2007550488 A JP 2007550488A JP 2008526876 A5 JP2008526876 A5 JP 2008526876A5
Authority
JP
Japan
Prior art keywords
composition
irna agent
antisense strand
nucleotides
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007550488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526876A (ja
JP5081630B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/000425 external-priority patent/WO2006074346A2/en
Publication of JP2008526876A publication Critical patent/JP2008526876A/ja
Publication of JP2008526876A5 publication Critical patent/JP2008526876A5/ja
Application granted granted Critical
Publication of JP5081630B2 publication Critical patent/JP5081630B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007550488A 2005-01-07 2006-01-06 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法 Expired - Fee Related JP5081630B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64236405P 2005-01-07 2005-01-07
US60/642,364 2005-01-07
US65982805P 2005-03-09 2005-03-09
US60/659,828 2005-03-09
PCT/US2006/000425 WO2006074346A2 (en) 2005-01-07 2006-01-06 RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011220918A Division JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Publications (3)

Publication Number Publication Date
JP2008526876A JP2008526876A (ja) 2008-07-24
JP2008526876A5 true JP2008526876A5 (cg-RX-API-DMAC7.html) 2009-02-19
JP5081630B2 JP5081630B2 (ja) 2012-11-28

Family

ID=36648197

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007550488A Expired - Fee Related JP5081630B2 (ja) 2005-01-07 2006-01-06 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2011220918A Expired - Fee Related JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2014113800A Pending JP2014156491A (ja) 2005-01-07 2014-06-02 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011220918A Expired - Fee Related JP5814728B2 (ja) 2005-01-07 2011-10-05 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法
JP2014113800A Pending JP2014156491A (ja) 2005-01-07 2014-06-02 ＲＳＶのＲＮＡｉ調節及びその治療上の使用方法

Country Status (14)

Country Link
US (8) US7507809B2 (cg-RX-API-DMAC7.html)
EP (4) EP1833490A4 (cg-RX-API-DMAC7.html)
JP (3) JP5081630B2 (cg-RX-API-DMAC7.html)
KR (1) KR101169668B1 (cg-RX-API-DMAC7.html)
CN (2) CN101119734B (cg-RX-API-DMAC7.html)
AT (1) ATE551421T1 (cg-RX-API-DMAC7.html)
AU (2) AU2006203934B2 (cg-RX-API-DMAC7.html)
CA (1) CA2594334A1 (cg-RX-API-DMAC7.html)
DK (1) DK2230304T3 (cg-RX-API-DMAC7.html)
EA (3) EA201201356A1 (cg-RX-API-DMAC7.html)
ES (1) ES2385811T3 (cg-RX-API-DMAC7.html)
IL (2) IL184162A (cg-RX-API-DMAC7.html)
NZ (1) NZ556097A (cg-RX-API-DMAC7.html)
WO (1) WO2006074346A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE60140676D1 (de) 2000-03-30 2010-01-14 Massachusetts Inst Technology Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind
CZ308053B6 (cs) 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US7592322B2 (en) * 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
AU2006203934B2 (en) 2005-01-07 2010-09-09 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV and therapeutic uses thereof
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
DK2308514T3 (da) 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
US20100215588A1 (en) * 2007-04-26 2010-08-26 Rami Skaliter Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
AU2008270209B2 (en) 2007-07-05 2012-05-17 Arrowhead Pharmaceuticals, Inc. dsRNA for treating viral infection
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2011506484A (ja) * 2007-12-13 2011-03-03 アルニラム ファーマシューティカルズ， インコーポレイテッド Ｒｓｖ感染の予防または治療のための方法および組成物
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2010048590A1 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
CA2764158A1 (en) * 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EP2495323A4 (en) * 2009-10-30 2014-04-30 Daiichi Sankyo Co Ltd MODIFIED DOUBLE-STRENGTH POLYNUCLEOTIDE
AU2010321885B2 (en) 2009-11-20 2015-12-24 The Regents Of The University Of California Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP2609198B8 (en) * 2010-08-24 2018-03-28 Sirna Therapeutics, Inc. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
PT2855435T (pt) 2012-05-29 2018-07-03 Parion Sciences Inc Aminoamidas do tipo dendrímeros possuindo atividade bloqueadora de canais de sódio para o tratamento do olho seco e outras doenças das mucosas
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
UA120343C2 (uk) 2012-12-17 2019-11-25 Періон Сайєнсіз, Інк. Похідні хлорпіразинкарбоксаміду, які мають активність блокування епітеліальних натрієвих каналів
KR20150137350A (ko) * 2014-05-29 2015-12-09 삼성전자주식회사 화상형성장치 및 화상형성장치의 스캔 방법
EP3340967B1 (en) 2015-08-24 2024-05-22 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
CN105693557A (zh) * 2016-01-04 2016-06-22 湖北卓熙氟化股份有限公司 一种氟化氢尿素及其制备方法
JP2018012236A (ja) * 2016-07-20 2018-01-25 株式会社東芝 印刷システム
CN108689886B (zh) * 2018-06-22 2021-06-15 湖北卓熙氟化股份有限公司 一种氟化氢尿素的制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
HU205839B (en) * 1987-11-18 1992-07-28 Chinoin Gyogyszer Es Vegyeszet Synergetic artropodicide composition containining pirethroides and phosphate-esters as active components
WO1995023225A2 (en) * 1994-02-23 1995-08-31 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5693532A (en) * 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
WO1997014792A2 (en) * 1995-10-17 1997-04-24 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
AU708535B2 (en) * 1996-02-15 1999-08-05 Cleveland Clinic Foundation, The RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
WO1998012312A1 (en) 1996-09-18 1998-03-26 Vanderbilt University Antisense gene therapy for rna viruses
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
CZ308053B6 (cs) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20060287267A1 (en) * 2001-05-18 2006-12-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2002313699A1 (en) 2001-07-20 2003-03-03 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
US6881835B2 (en) 2002-01-04 2005-04-19 Dr. Chip Biotechnology Inc. Detection of respiratory viruses
WO2003062258A1 (en) 2002-01-22 2003-07-31 The Cleveland Clinic Foundation Rnase l activator-antisense complexes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
WO2004042002A2 (en) 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2500468A1 (en) * 2002-09-28 2004-04-08 Massachussets Institute Of Technology Influenza therapeutic
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
ATE479752T1 (de) 2003-03-07 2010-09-15 Alnylam Pharmaceuticals Inc Therapeutische zusammensetzungen
JP2006522158A (ja) * 2003-04-03 2006-09-28 アルナイラム ファーマシューティカルズ インコーポレイテッド ｉＲＮＡ複合体
AU2004232964B2 (en) 2003-04-17 2011-09-22 Alnylam Pharmaceuticals, Inc. Protected monomers
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾ｉＲＮＡ剤
TW572579U (en) * 2003-05-12 2004-01-11 Enermax Technology Corp Power supply still capable of dissipating heat after powering off a computer
JP2007524397A (ja) 2003-07-03 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア Ｓｙｋキナーゼ発現の阻害
CN101044152A (zh) * 2004-02-05 2007-09-26 因特拉迪格姆公司 组合RNAi治疗的方法和组合物
JP2007531794A (ja) * 2004-04-05 2007-11-08 アルニラム ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US7592322B2 (en) * 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
CA2586250A1 (en) * 2004-11-05 2006-11-16 Intradigm Corporation Compositions for treating respiratory viral infections and their use
AU2006203934B2 (en) 2005-01-07 2010-09-09 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV and therapeutic uses thereof
JP2008537551A (ja) 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
US20070213293A1 (en) 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
EP2008274B1 (en) 2006-03-31 2015-05-27 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of eg5 gene
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2009055445A2 (en) 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2011506484A (ja) 2007-12-13 2011-03-03 アルニラム ファーマシューティカルズ， インコーポレイテッド Ｒｓｖ感染の予防または治療のための方法および組成物
WO2010048590A1 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules

Similar Documents

Publication Publication Date Title
JP2008526876A5 (cg-RX-API-DMAC7.html)
EA201201356A1 (ru) Композиция для лечения респираторных синцитиальных вирусов
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
JP7007304B2 (ja) Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子
EP2421970B1 (en) Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
JP4718379B2 (ja) 修飾された低分子干渉ｒｎａ分子および使用方法
JP2008283975A5 (cg-RX-API-DMAC7.html)
JP2020094063A5 (cg-RX-API-DMAC7.html)
JP2007529224A5 (cg-RX-API-DMAC7.html)
JP2009514877A5 (cg-RX-API-DMAC7.html)
JP2008517940A5 (cg-RX-API-DMAC7.html)
EA200870528A1 (ru) Композиции и способы ингибирования экспрессии гена pcsk9
JP2011511636A5 (cg-RX-API-DMAC7.html)
JP2016513976A5 (cg-RX-API-DMAC7.html)
RU2010139908A (ru) Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение
WO2007127919A3 (en) Compositions and methods for inhibiting expression of a gene from the jc virus
TW202120689A (zh) 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
CN114846140A (zh) 用于治疗hbv的靶向hbv的治疗性寡核苷酸和tlr7激动剂的药物组合
WO2007111998A3 (en) Dsrna compositions and methods for treating hpv infection
JP2004537030A5 (cg-RX-API-DMAC7.html)
US20050059617A1 (en) Novel anitsense oligonucleotide derivatives against to hepatitis c virus
EP1945270A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V LEIDEN GENE MUTATION
WO2008109493A4 (en) NUCLEIC ACID COMPOUNDS DESIGNED TO INHIBIT EXPRESSION OF CD19 GENE AND USES THEREOF
WO2008109520A4 (en) Nucleic acid compounds for inhibiting cxc gene expression and uses thereof
WO2008109503B1 (en) Nucleic acid compounds for inhibiting ms4a1 gene expression and uses thereof